Literature DB >> 19380476

M-cell targeting of whole killed bacteria induces protective immunity against gastrointestinal pathogens.

Yok-Teng Chionh1, Janet L K Wee, Alison L Every, Garrett Z Ng, Philip Sutton.   

Abstract

As the majority of human pathogens infect via a mucosal surface, delivery of killed vaccines by mucosal routes could potentially improve protection against many such organisms. Our ability to develop effective killed mucosal vaccines is inhibited by a lack of adjuvants that are safe and effective in humans. The Ulex europaeus agglutinin I (UEA-I) lectin specifically binds M cells lining the murine gastrointestinal tract. We explored the potential for M-cell-targeted vaccination of whole, killed Helicobacter pylori, the main causative agent of peptic ulcer disease and gastric cancer, and Campylobacter jejuni, the most common cause of diarrhea. Oral delivery of UEA-I-agglutinated H. pylori or C. jejuni induced a significant increase in both serum and intestinal antibody levels. This elevated response (i) required the use of whole bacteria, as it did not occur with lysate; (ii) was not mediated by formation of particulate clumps, as agglutination with a lectin with a different glycan specificity had no effect; and (iii) was not due to lectin-mediated, nonspecific immunostimulatory activity, as UEA-I codelivery with nonagglutinated bacteria did not enhance the response. Vaccination with UEA-I-agglutinated, killed whole H. pylori induced a protective response against subsequent live challenge that was as effective as that induced by cholera toxin adjuvant. Moreover, vaccination against C. jejuni by this approach resulted in complete protection against challenge in almost all animals. We believe that this is the first demonstration that targeting of whole killed bacteria to mucosal M cells can induce protective immunity without the addition of an immunostimulatory adjuvant.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19380476      PMCID: PMC2708587          DOI: 10.1128/IAI.01522-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  Therapeutic immunization against Helicobacter pylori infection in the absence of antibodies.

Authors:  P Sutton; J Wilson; T Kosaka; I Wolowczuk; A Lee
Journal:  Immunol Cell Biol       Date:  2000-02       Impact factor: 5.126

2.  Immunological implications of the use of plant lectins for drug and vaccine targeting to the gastrointestinal tract.

Authors:  E C Lavelle; G Grant; U Pfuller; D T O'Hagan
Journal:  J Drug Target       Date:  2004-02       Impact factor: 5.121

3.  Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy.

Authors:  Robert B Couch
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245

Review 4.  M cell targeting by lectins: a strategy for mucosal vaccination and drug delivery.

Authors:  Mark A Jepson; M Ann Clark; Barry H Hirst
Journal:  Adv Drug Deliv Rev       Date:  2004-03-03       Impact factor: 15.470

5.  Investigation of infection with Campylobacter jejuni in a man with hypogammaglobulinaemia using PCR-single-stranded conformational polymorphism (PCR-SSCP) typing.

Authors:  J Moore; M Curran; D Wareing; A Fox; N Boyd; G Glynn; B Millar; G Daly; P Murphy
Journal:  Int J Med Microbiol       Date:  2001-04       Impact factor: 3.473

6.  Post-immunisation gastritis and Helicobacter infection in the mouse: a long term study.

Authors:  P Sutton; S J Danon; M Walker; L J Thompson; J Wilson; T Kosaka; A Lee
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

7.  Protection against experimental Helicobacter pylori infection after immunization with inactivated H. pylori whole-cell vaccines.

Authors:  S Raghavan; M Hjulström; J Holmgren; A-M Svennerholm
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

8.  Intestinal villous M cells: an antigen entry site in the mucosal epithelium.

Authors:  Myoung Ho Jang; Mi-Na Kweon; Koichi Iwatani; Masafumi Yamamoto; Kazutaka Terahara; Chihiro Sasakawa; Toshihiko Suzuki; Tomonori Nochi; Yoshifumi Yokota; Paul D Rennert; Takachika Hiroi; Hiroshi Tamagawa; Hideki Iijima; Jun Kunisawa; Yoshikazu Yuki; Hiroshi Kiyono
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-07       Impact factor: 11.205

9.  Immunogenicity and protective efficacy of a prototype Campylobacter killed whole-cell vaccine in mice.

Authors:  S Baqar; L A Applebee; A L Bourgeois
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

10.  A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses.

Authors:  Tomonori Nochi; Yoshikazu Yuki; Akiko Matsumura; Mio Mejima; Kazutaka Terahara; Dong-Young Kim; Satoshi Fukuyama; Kiyoko Iwatsuki-Horimoto; Yoshihiro Kawaoka; Tomoko Kohda; Shunji Kozaki; Osamu Igarashi; Hiroshi Kiyono
Journal:  J Exp Med       Date:  2007-11-05       Impact factor: 14.307

View more
  16 in total

Review 1.  Sampling of the intestinal microbiota by epithelial M cells.

Authors:  Joseph M Pickard; Alexander V Chervonsky
Journal:  Curr Gastroenterol Rep       Date:  2010-10

Review 2.  Intestinal epithelial glycosylation in homeostasis and gut microbiota interactions in IBD.

Authors:  Matthew R Kudelka; Sean R Stowell; Richard D Cummings; Andrew S Neish
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-07-24       Impact factor: 46.802

3.  Targeting of whole killed bacteria to gastrointestinal M-cells induces humoral immunity in the female reproductive tract.

Authors:  Yok-Teng Chionh; Philip Sutton
Journal:  Gut Microbes       Date:  2010-01

Review 4.  Identifying human and murine M cells in vitro.

Authors:  Ana Klisuric; Benjamin Thierry; Ludivine Delon; Clive A Prestidge; Rachel J Gibson
Journal:  Exp Biol Med (Maywood)       Date:  2019-03-24

Review 5.  Endothelial progenitor cells: quo vadis?

Authors:  Matthew R Richardson; Mervin C Yoder
Journal:  J Mol Cell Cardiol       Date:  2010-07-29       Impact factor: 5.000

6.  Protease-activated receptor 1 suppresses Helicobacter pylori gastritis via the inhibition of macrophage cytokine secretion and interferon regulatory factor 5.

Authors:  Y-T Chionh; G Z Ng; L Ong; A Arulmuruganar; A Stent; M A Saeed; J Lk Wee; P Sutton
Journal:  Mucosal Immunol       Date:  2014-05-28       Impact factor: 7.313

Review 7.  Transepithelial antigen delivery in the small intestine: different paths, different outcomes.

Authors:  Kathryn A Knoop; Mark J Miller; Rodney D Newberry
Journal:  Curr Opin Gastroenterol       Date:  2013-03       Impact factor: 3.287

Review 8.  Enhancing oral vaccine potency by targeting intestinal M cells.

Authors:  Ali Azizi; Ashok Kumar; Francisco Diaz-Mitoma; Jiri Mestecky
Journal:  PLoS Pathog       Date:  2010-11-11       Impact factor: 6.823

9.  RANKL is necessary and sufficient to initiate development of antigen-sampling M cells in the intestinal epithelium.

Authors:  Kathryn A Knoop; Nachiket Kumar; Betsy R Butler; Senthilkumar K Sakthivel; Rebekah T Taylor; Tomonori Nochi; Hisaya Akiba; Hideo Yagita; Hiroshi Kiyono; Ifor R Williams
Journal:  J Immunol       Date:  2009-10-14       Impact factor: 5.422

Review 10.  Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium.

Authors:  N A Mabbott; D S Donaldson; H Ohno; I R Williams; A Mahajan
Journal:  Mucosal Immunol       Date:  2013-05-22       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.